12:00 AM
Sep 23, 2013
 |  BC Week In Review  |  Company News  |  Sales & Marketing

Chugai sales and marketing update

Chugai launched Perjeta pertuzumab in Japan to treat HER2-positive inoperable or recurrent breast cancer. The Japanese National Health Insurance (NHI) list price is ¥231,866 ($2,331) for a 420 mg/14 mL vial. The...

Read the full 150 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >